Update on Polio Vaccine and Lymphoma
DR. MERCOLA'S COMMENT:
Last issue I posted
an article
from Lancet showing that half of the 55,000 cases of non-Hodgkin lymphoma in
the US are likely related to contaminated polio vaccine.
The researchers believed that the contaminated vaccine batches were cleared up in 1963. A reader forwarded me a peer reviewed journal article discussing the legal proceedings at Lederle that suggest otherwise.
I have posted the abstract of the article below:
To date, the scientific
literature and research examining SV40 and cancer-related diseases has been
based upon an assumption that SV40 was not present in any poliovirus vaccine
administered in the United States and was removed from the killed polio
vaccine by 1963.
The basis for this presumption has been that the regulations for live oral
polio vaccine required that SV40 be removed from the seeds and monovalent
pools ultimately produced in the manufacturing process.
The Division of Biologic Standards permitted an additional two tissue
culture passages -- from three to five -- in order to allow manufacturers
the ability to remove this contaminant from the oral poliovirus vaccines
then awaiting licensure. The confirmation of the removal by one drug
manufacturer, Lederle, has been made public at an international symposium in
January 1997, where its representatives stated that all of Lederle's seeds
had been tested and screened to assure that it was free from SV40 virus.
However, in litigation involving the Lederle oral polio vaccine, the
manufacturer's internal documents failed
to reveal such removal in all of the seeds. The absence of
confirmatory testing of the seeds, as well as testimony of a Lederle
manager, indicate that this claim of removal of SV40 and the testing for
SV40 in all the seeds cannot be fully substantiated.
These legal documents and testimony indicate that the scientific community
should not be content with prior assumptions that SV40 could not have been
in the oral polio vaccine.
Only further investigation by outside scientific and independent researchers
who can review the test results claimed in the January 1997 meeting and who
can conduct their own independent evaluations by testing all the seeds and
individual mono-valent pools will assure that SV40 has not been present in
commercially sold oral poliovirus vaccine manufactured by Lederle.
Anticancer Res 2000 Nov-Dec;20(6C):4745-9